Advantage Austria Show navigation

Baxter Concentrates Research and Development in Austria

Baxter
April 30, 2008

Global Pharmaceutical Concern Continues to Expand its Presence

Baxter is investing about 40 million USD annually to expand its research facilities. It is now bringing the global research and development activities of its BioScience Division with yearly sales of approx. 4.6 billion USD under one roof in a newly established company.

The new Baxter Innovation GmbH, headquartered in Vienna, should make the separation between the research department and the renal and medication delivery departments more clear. “In this way we are enhancing the research done in Austria and utilized throughout the world,” says Markus Reinhard, Baxter CEO and head of the Baxter Innovation division.

This fiscal year Baxter has spent roughly 400 million USD on the restructuring. Most of the money will be spent on the research laboratory expansion and on the facility at Orth an der Donau, where Baxter runs Austria’s largest research department. For the following years, Baxter is planning similar expenditures. Currently 840 people are employed in primary research and related R & D areas. By the end of 2008 this figure should rise to about 1,000. Of those, 75% will be located in Austria. A few might be ex-Novartis employees. According to Austria boss Reinhard, “We recently introduced a definitive job profile for open positions.”

Baxter Austria

Baxter Austria employs more than 75% of all scientists working worldwide for Baxter BioScience. 3200 employees in Austria make it the largest location outside the USA.

Baxter Worldwide

In the last fiscal year Baxter International Inc., with its 47,000 employees worldwide, increased its consolidated sales by 9% to 11.3 billion USD.

The company, which is headquartered in Deerfield, IL, invested 760 million USD worldwide in research and development in 2007.

print
©©ADVANTAGE AUSTRIA